

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elazar Rabbani et al.

Serial No. 08/978,636

Filed: November 25, 1997

Group Art Unit: 1635

Ex'r: Andrew Wang



NOVEL PROPERTY EFFECTING
AND/OR PROPERTY EXHIBITING
COMPOSITIONS FOR THERAPEUTIC
AND DIAGNOSTIC USE

527 Madison Avenue, 9th Floor
New York, New York 10022
October 26, 1998

FILED BY EXPRESS MAIL

Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

Attention: **Box Sequence**

**COMMUNICATION DIRECTED TO NOTICE
TO COMPLY WITH SEQUENCE RULES**



Dear Sirs:

This Communication is directed to the Notice To Comply With Sequence Rules that was attached to the Notice to File Missing Parts of Application – Filing Date Granted that was mailed on April 24, 1998 in connection with the above-identified application.

In response to the sequence notice, Applicants hereby submit the following documents or items:

1. A Request For An Extension Of Time (Five Months) Under 37 C.F.R. §1.136(a);
2. A copy of the Notice To Comply With Requirements For Patent Application Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures Under 37 C.F.R. §§1.821-1.825.

ENZ-53(D3)


EXPRESS MAIL CERTIFICATE	
Express Mail Label No.	EM366566219
Date of Deposit	OCTOBER 26, 1998
I hereby certify that the contents and the attachments herein are true and correct copies of the original documents submitted to the United States Patent and Trademark Office to comply with the requirements of 37 C.F.R. 1.821 on the date indicated above and addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
 Ronald C. Fedus Reg. No. 12,567	 Date

3. initial paper copy of the "Sequence Listing;"
4. Amendment directing entry of the "Sequence Listing into the specification;
5. computer readable form (CFR) copy of the "Sequence Listing;" and
6. Declaration Under 37 C.F.R. §1.821(g) attesting that the content of the paper and computer readable copies are the same and include no new matter.

No fee is believed due in connection with this Communication or the documents or items submitted herewith other than the fee payment authorized in the Request For an Extension Of time (Five Months) Under 37 C.F.R. §1.136(a). If any other fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, Inc.
527 Madison Avenue (9th Fl)
New York, New York 10022
(212) 583-0100

LC:\USProsecution\Enz53(D3)\6\communication re sequence rules102398 3nz53d3

ENZ-53(D3)